DiaMedica Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview

DiaMedica Therapeutics

07/08/2026 23:02

DiaMedica Therapeutics Inc DMAC.OQ DMAC.O is expected to  show no change in quarterly revenue when it reports  results on August 10 for the period ending June 30 2026

​LSEG's mean analyst estimate for DiaMedica Therapeutics Inc is for a loss of 20 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for DiaMedica Therapeutics Inc is $13.00, about 92% above its last closing price of $6.77
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.18
-0.18
-0.19
Missed
-2.7
Dec. 31 2026
-0.18
-0.17
Beat
5.6
Sep. 30 2025
-0.16
-0.16
-0.17
Missed
-6.2​
Jun. 30 2025
-0.18
-0.19
-0.18
Beat
5.3
​​Mar. 31 2025
-0.17
-0.18
-0.18
Met
0
Dec. 31 2024
-0.17
-0.18
Missed
-4.3​
Sep. 30 2024
-0.15
-0.15
-0.15
Met
3.2
Jun. 30 2024
-0.15
-0.16
-0.13
Beat
17
This summary was machine generated August 7 at 22:02 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)